Wednesday 15th February 2023
|Text too small?|
Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company), is pleased to provide this commercial update.
TruScreen successfully secured a tender for the supply of a further 10,800 SUS (Single Use Sensor) which is expected to be shipped in March 2023.
The TruScreen cervical cancer screening roll out in Zimbabwe continues to make excellent progress with the programme scanning 10,500 women in the Masvingo province at the end of January 2023. TruScreen continues to work closely with the National Aids Council and the Ministry of Health in support of its plan to implement the programme nationally.
TruScreen anticipates that Vietnam will become a market of major focus with significant potential. Our new Vietnamese distributor has recently placed an order for 8 devices and 1,800 SUS which will be shipped in March 2023. The devices will be installed in 8 hospitals with screenings expected to commence in Q2 CY2023.
From the pipeline of potential hospitals, TruScreen expects further approvals to follow. TruScreen is also expecting to receive local accreditation shortly, thereby removing the requirement for individual hospitals to seek prior MOH approval, which will shorten the sales cycle.
On the strength of our Russian distributors expansion into Kazakhstan and to accelerate screening programmes in Russia and neighbouring Central Asian countries, JSC IMSystems have upgraded their order, for which payment has been received, to 11 devices and 6,120 SUS.
TruScreen’s Russia distributor JSC IMSystems has recently extended its presence to Kazakhstan which will be the base of expansion by IMSystems to other Central Asian countries. Kazakhstan has a population of 18 million spread over an area of 2.7 million square kilometres (the 9th largest country in the world). Central Asian doctors and healthcare professionals are mostly trained in Russian universities and hospitals.
Middle East and Gulf Countries
Saudi Arabia will shortly announce the results of its TruScreen cervical cancer screening clinical trial programme. TruScreen expects the results to be positive and it will endorse the TruScreen cervical cancer screening technology, with sales of devices to our distributor to follow. Opportunities to expand in the Middle East and Gulf countries are also being evaluated with discussions underway for distribution rights in Jordan.
With China re-opening her borders for international travel in January 2023, we expect the market to swiftly return to normal trading. China remains TruScreen’s major market. TruScreen cervical cancer screening devices are registered as a Chinese domestic product with its Made in China mark.
The manufacturing of devices marketed in China being made in China shortens the selling cycle in China and provides a significant barrier of entry for competing foreign technologies seeking to access the Chinese market.
Following the sales referred to above TruScreen will have 238 TruScreen Screening Devices operating in the field with a commensurate increasing pull through in SUS usage. A disposal SUS is used in every single screening test. This is a 26.6% increase of devices in operation at the end of FY2022.
This announcement has been approved by the Board.
No comments yet
CHI - Director changes at Channel Infrastructure
December 6th Morning Report
December 5th Morning Report
TWR - Tower announces strategic review
PFI - 11 Sheffield Street, Blenheim Divestment
December 4th Morning Report
Me Today - Notice of Annual Shareholder Meeting
FSF - Director Scott St John to retire from Fonterra Board
Greenfern announces change in Chief Financial Officer
AIA Provision of Financial Assistance - Employee Share Plan